Minerva Neurosciences | NERV - Debt


Minerva Neurosciences reported $0 in Debt for its fiscal quarter ending in September of 2024.





Debt Change Date
Acadia Pharmaceuticals USD 54.81M 1.48M Sep/2025
Adma Biologics USD 83.12M 702K Sep/2025
ALKERMES USD 71.6M 1.08M Sep/2025
Alterity Therapeutics Limited AUD 210.39K 120.67K Jun/2023
AstraZeneca USD 32.63B 207M Sep/2025
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Bristol-Myers Squibb USD 51.04B 112M Sep/2025
Cipla INR 4.38B 231.9M Mar/2025
Clal Biotechnology ILS 35.76M 28.27M Dec/2023
Compugen USD 2.95M 24K Sep/2025
CSL USD 11.96B 219M Dec/2024
Eli Lilly USD 42.51B 2.6B Sep/2025
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
GlaxoSmithKline GBP 17.75B 396M Sep/2025
Grifols EUR 9.23B 626.05M Dec/2024
Halozyme Therapeutics USD 1.51B 1.66M Sep/2025
Ionis Pharmaceuticals USD 2.33B 1.1B Dec/2025
J&J USD 45.8B 4.97B Sep/2025
Merck USD 41.37B 5.97B Sep/2025
Minerva Neurosciences USD 0 0 Sep/2024
Neurocrine Biosciences USD 428.4M 10.7M Sep/2025
Novartis USD 32.64B 1.37B Jun/2025
Novavax USD 233.31M 4.23M Sep/2024
Pfizer USD 60.85B 78M Sep/2025
Roche Holding CHF 33.03B 1.41B Jun/2025
Sanofi EUR 21.76B 530M Sep/2025
Takeda JPY 4.85T 208B Dec/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024